Alnylam Launches Digital Tool for ATTR Amyloidosis Patients in UK
The Alnylam has been a pioneer in the hereditary ATTR amyloidosis, along with getting the approval in the year 2018 for the first drug for the purpose of treating the rare disease, and it has also launched a digital companion for the purpose of helping the patients for tracking their symptoms. The new app of […]
Continue Reading